 Past studies conducted at the Myeloma Institute have shown that many patients with low-risk disease as determined by gene array studies - studies that look at specific genes using special equipment respond very well to treatment. However, about 15 of low-risk patients still relapse during the first three years of treatment, which means that better treatments are still needed. 